CRISPR Therapeutics KUV 2024

Mitä CRISPR Therapeutics tekee?

CRISPR Therapeutics AG is a company specializing in the development of therapies based on the gene editing technology CRISPR-Cas9. The company was founded in 2013 in Basel, Switzerland and is now headquartered in Zug, Switzerland. CRISPR Therapeutics is listed on the NASDAQ stock exchange and also has offices in the USA and London. CRISPR Therapeutics AG's history is closely linked to the discovery and development of the CRISPR-Cas9 technology. This revolutionary technique allows for the targeted modification, repair or elimination of certain genes in the genome of organisms. The technology was first discovered in the 1990s, but it was only in recent years with the development of CRISPR-Cas9 that it became possible to apply this technique in medical research. The goal of CRISPR Therapeutics AG is to use the CRISPR-Cas9 technology to develop therapies for life-threatening genetic diseases. The company works closely with the academic community and industry to develop innovative therapies and bring them through clinical trials. The business model of CRISPR Therapeutics AG is based on the development and commercialization of therapies based on the CRISPR-Cas9 technology. This involves using the technology to treat the genetic causes of serious diseases such as cystic fibrosis, sickle cell anemia, beta-thalassemia, or certain types of cancer. The company has a number of products in its pipeline and works closely with partners such as Vertex Pharmaceuticals and Bayer. CRISPR Therapeutics operates in the biotechnology industry and is divided into various divisions. For example, there is the research and development (R&D) division, which focuses on developing new therapies based on the CRISPR-Cas9 technology. Here, the company works on its own research projects as well as joint research projects with partners. There is also a clinical studies department that aims to test new therapies, prove their efficacy and safety in humans, and produce approved therapeutics. An example of a current product from the company is the CTX001 therapy, which involves stem cell transplantation using genetically modified stem cells from healthy donors to produce genetically error-free blood cells in the patient's body. CTX001 is currently in phase 1/2a clinical trials for the treatment of beta-thalassemia and sickle cell anemia, and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. In summary, CRISPR Therapeutics AG is a company in the biotechnology industry specializing in the development and commercialization of therapies based on the CRISPR-Cas9 technology. The company has a number of products in its pipeline and works closely with partners to develop innovative therapies and bring them through clinical trials. With the CRISPR-Cas9 technology, there is the potential to combat genetic diseases, which could have a significant impact on the treatment of diseases in the future. CRISPR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.